Orient Europharma Co Ltd Net Assets
Orient Europharma Co Ltd net assets. Based on the latest financial reports, Orient Europharma Co Ltd (4120) has net assets worth NT$7.89 Billion TWD (≈ $248.61 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$12.43 Billion ≈ $391.55 Million USD) and total liabilities (NT$4.54 Billion ≈ $142.94 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 4120 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$7.89 Billion |
| % of Total Assets | 63.49% |
| Annual Growth Rate | 6.22% |
| 5-Year Change | 49.15% |
| 10-Year Change | N/A |
| Growth Volatility | 15.04 |
Net Assets of Orient Europharma Co Ltd (2015–2024)
Net assets of Orient Europharma Co Ltd from 2015 to 2024. This chart illustrates how Orient Europharma Co Ltd's net assets have evolved over time, based on quarterly financial data. See Orient Europharma Co Ltd (4120) net asset quality to measure how much of total assets are equity-financed.
Annual Net Assets for Orient Europharma Co Ltd (2015–2024)
The table below shows the annual net assets of Orient Europharma Co Ltd from 2015 to 2024. For live market cap and overall valuation, see 4120 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$5.82 Billion ≈ $183.50 Million |
+39.93% |
| 2023-12-31 | NT$4.16 Billion ≈ $131.14 Million |
+20.87% |
| 2022-12-31 | NT$3.44 Billion ≈ $108.50 Million |
-0.27% |
| 2021-12-31 | NT$3.45 Billion ≈ $108.79 Million |
-11.57% |
| 2020-12-31 | NT$3.91 Billion ≈ $123.03 Million |
+2.45% |
| 2019-12-31 | NT$3.81 Billion ≈ $120.09 Million |
-7.98% |
| 2018-12-31 | NT$4.14 Billion ≈ $130.50 Million |
+1.08% |
| 2017-12-31 | NT$4.10 Billion ≈ $129.11 Million |
+4.64% |
| 2016-12-31 | NT$3.92 Billion ≈ $123.38 Million |
+15.71% |
| 2015-12-31 | NT$3.38 Billion ≈ $106.63 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Orient Europharma Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3.3% over the analyzed period, indicating profitable operations and earnings retention.
Orient Europharma Co Ltd Net Assets Breakdown (December 2024)
Orient Europharma Co Ltd net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$1.60 Billion | 30.96% |
| Other Components | NT$3.57 Billion | 69.04% |
| Total Equity | NT$5.16 Billion | 100.00% |
Orient Europharma Co Ltd Competitors by Market Cap
The table below lists competitors of Orient Europharma Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MingZhu Logistics Holdings Ltd
NASDAQ:YGMZF
|
$13.49K |
|
Alpine 4 Holdings Inc
NASDAQ:ALPP
|
$13.53K |
|
Mothercare PLC
LSE:MTC
|
$13.72K |
|
Harvest Minerals Ltd
LSE:HMI
|
$13.77K |
|
Hornby PLC
LSE:HRN
|
$13.31K |
|
Eos Energy Enterprises Inc
NASDAQ:EOSEW
|
$13.24K |
|
Adomos SA
PA:ALADO
|
$13.13K |
|
Bolt Projects Holdings, Inc.
NASDAQ:BSLK
|
$13.10K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Orient Europharma Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,514,485,000 to 5,164,037,000, a change of 1,649,552,000 (46.9%).
- Net loss of 283,934,000 reduced equity.
- Dividend payments of 100,963,000 reduced retained earnings.
- Other factors increased equity by 2,034,449,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-283.93 Million | -5.5% |
| Dividends Paid | NT$100.96 Million | -1.96% |
| Other Changes | NT$2.03 Billion | +39.4% |
| Total Change | NT$- | 46.94% |
Book Value vs Market Value Analysis
This analysis compares Orient Europharma Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.72x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.13x to 0.72x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$37.67 | NT$42.75 | x |
| 2018-12-31 | NT$37.84 | NT$42.75 | x |
| 2019-12-31 | NT$36.83 | NT$42.75 | x |
| 2020-12-31 | NT$36.99 | NT$42.75 | x |
| 2021-12-31 | NT$33.91 | NT$42.75 | x |
| 2022-12-31 | NT$33.76 | NT$42.75 | x |
| 2023-12-31 | NT$40.51 | NT$42.75 | x |
| 2024-12-31 | NT$59.53 | NT$42.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Orient Europharma Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6.47%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 2.24x
- Recent ROE (-5.50%) is below the historical average (5.02%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 7.72% | 4.55% | 0.90x | 1.89x | NT$-65.98 Million |
| 2016 | 14.93% | 8.98% | 0.81x | 2.06x | NT$155.13 Million |
| 2017 | 14.04% | 8.78% | 0.79x | 2.04x | NT$131.94 Million |
| 2018 | 7.52% | 4.48% | 0.76x | 2.21x | NT$-81.55 Million |
| 2019 | 7.75% | 4.06% | 0.77x | 2.46x | NT$-71.79 Million |
| 2020 | 6.21% | 3.70% | 0.66x | 2.54x | NT$-121.57 Million |
| 2021 | 4.09% | 2.52% | 0.51x | 3.20x | NT$-174.00 Million |
| 2022 | -10.61% | -6.57% | 0.45x | 3.56x | NT$-603.70 Million |
| 2023 | 4.10% | 3.13% | 0.42x | 3.08x | NT$-207.51 Million |
| 2024 | -5.50% | -6.47% | 0.38x | 2.24x | NT$-800.34 Million |
Industry Comparison
This section compares Orient Europharma Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $5,409,701,300
- Average return on equity (ROE) among peers: 9.40%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Orient Europharma Co Ltd (4120) | NT$7.89 Billion | 7.72% | 0.57x | $13.45K |
| Grape King Bio Ltd (1707) | $3.72 Billion | 25.36% | 0.44x | $386.90 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $2.91 Billion | 7.21% | 0.55x | $315.84 Million |
| Maywufa Co Ltd (1731) | $1.17 Billion | 7.46% | 1.06x | $87.31 Million |
| ScinoPharm Taiwan Ltd (1789) | $9.07 Billion | 12.91% | 0.14x | $493.27 Million |
| Lotus Pharmaceutical Co Ltd (1795) | $23.78 Billion | 19.85% | 3.46x | $1.35 Billion |
| GeneFerm Biotechnology Co Ltd (1796) | $416.51 Million | 2.48% | 0.34x | $34.68 Million |
| LIWANLI Innovation Co Ltd (3054) | $382.24 Million | 0.00% | 1.52x | $144.33 Million |
| YungShin Global Holding Corp (3705) | $5.01 Billion | 14.43% | 0.38x | $497.64 Million |
| TTY Biopharm Co Ltd (4105) | $6.08 Billion | 15.21% | 0.54x | $618.09 Million |
| Phytohealth Corp (4108) | $1.56 Billion | -10.88% | 0.06x | $69.46 Million |
About Orient Europharma Co Ltd
Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs worldwide. Its prescription medicines include cardiovascular, metabolism, neurology, obstetrics and gynecology, respiratory, andrology, immunology, antibiotic, and anti-cancer drugs. The company also provides nutrition and baby care products, such as milk under the Karihome brand name; and healthcare supplement… Read more